Business Description
BeiGene Ltd
NAICS : 325412
SIC : 2834
ISIN : US07725L1026
Compare
Compare
Traded in other countries / regions
688235.China06160.Hong KongBGNE.USA49B.GermanyB1GN34.BrazilBGNE.Mexico IPO Date
2016-02-03Description
BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.19 | |||||
| Equity-to-Asset | 0.66 | |||||
| Debt-to-Equity | 0.18 | |||||
| Debt-to-EBITDA | -0.45 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 4.64 | |||||
| Beneish M-Score | 0.62 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 24.4 | |||||
| 3-Year EBITDA Growth Rate | -2.2 | |||||
| 3-Year EPS without NRI Growth Rate | -6.9 | |||||
| 3-Year FCF Growth Rate | -8 | |||||
| 3-Year Book Growth Rate | 39.1 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 27.06 | |||||
| 9-Day RSI | 35.65 | |||||
| 14-Day RSI | 40.49 | |||||
| 6-1 Month Momentum % | -9.91 | |||||
| 12-1 Month Momentum % | 34.89 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.13 | |||||
| Quick Ratio | 2.9 | |||||
| Cash Ratio | 2.5 | |||||
| Days Inventory | 52.24 | |||||
| Days Sales Outstanding | 46.1 | |||||
| Days Payable | 46.34 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -19.2 | |||||
| Shareholder Yield % | 0.22 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -12.19 | |||||
| Operating Margin % | -88.19 | |||||
| Net Margin % | -95.67 | |||||
| ROE % | -38.85 | |||||
| ROA % | -26.93 | |||||
| ROIC % | -83.98 | |||||
| ROC (Joel Greenblatt) % | -166.8 | |||||
| ROCE % | -31.65 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 11.06 | |||||
| PB Ratio | 5.31 | |||||
| Price-to-Tangible-Book | 5.38 | |||||
| EV-to-EBIT | -10.87 | |||||
| EV-to-Forward-EBIT | -19.18 | |||||
| EV-to-EBITDA | -11.42 | |||||
| EV-to-Forward-EBITDA | -16.99 | |||||
| EV-to-Revenue | 9.58 | |||||
| EV-to-Forward-Revenue | 5.93 | |||||
| EV-to-FCF | -8.72 | |||||
| Price-to-Net-Current-Asset-Value | 8.17 | |||||
| Price-to-Net-Cash | 12.72 | |||||
| Earnings Yield (Greenblatt) % | -9.2 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BGNE
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BeiGene Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1,810.785 | ||
| EPS (TTM) ($) | -16.698 | ||
| Beta | 0.09 | ||
| Volatility % | 58.47 | ||
| 14-Day RSI | 40.49 | ||
| 14-Day ATR ($) | 8.725369 | ||
| 20-Day SMA ($) | 202.8655 | ||
| 12-1 Month Momentum % | 34.89 | ||
| 52-Week Range ($) | 124.46 - 280.6199 | ||
| Shares Outstanding (Mil) | 105.76 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BeiGene Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BeiGene Ltd Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
BeiGene Ltd Frequently Asked Questions
What is BeiGene Ltd(BGNE)'s stock price today?
The current price of BGNE is $190.58. The 52 week high of BGNE is $280.62 and 52 week low is $124.46.
When is next earnings date of BeiGene Ltd(BGNE)?
The next earnings date of BeiGene Ltd(BGNE) is 2023-11-09 Est..
Does BeiGene Ltd(BGNE) pay dividends? If so, how much?
BeiGene Ltd(BGNE) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers